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Abstract
Background: While clinical outcomes following immunotherapy have shown an association with tumor mutation
load using whole exome sequencing (WES), its clinical applicability is currently limited by cost and bioinformatics
requirements.
Methods: We developed a method to accurately derive the predicted total mutation load (PTML) within individual
tumors from a small set of genes that can be used in clinical next generation sequencing (NGS) panels. PTML was
derived from the actual total mutation load (ATML) of 575 distinct melanoma and lung cancer samples and
validated using independent melanoma (n = 312) and lung cancer (n = 217) cohorts. The correlation of PTML
status with clinical outcome, following distinct immunotherapies, was assessed using the Kaplan–Meier method.
Results: PTML (derived from 170 genes) was highly correlated with ATML in cutaneous melanoma and lung
adenocarcinoma validation cohorts (R2 = 0.73 and R2 = 0.82, respectively). PTML was strongly associated with
clinical outcome to ipilimumab (anti-CTLA-4, three cohorts) and adoptive T-cell therapy (1 cohort) clinical outcome in
melanoma. Clinical benefit from pembrolizumab (anti-PD-1) in lung cancer was also shown to significantly
correlate with PTML status (log rank P value < 0.05 in all cohorts).
Conclusions: The approach of using small NGS gene panels, already applied to guide employment of targeted
therapies, may have utility in the personalized use of immunotherapy in cancer.
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Background
There is a strong impetus to personalize the care of
cancer patients to deliver selective therapies. One way
this is being done clinically is by performing next-
generation sequencing (NGS) on panels of cancer-
related genes to identify targeted therapy approaches to
which patients are most likely to respond. While a
number of ongoing targeted therapy trials are utilizing
this approach to optimize patient selection, in parallel,
new immunotherapies have shown remarkable anti-cancer
effects in melanoma and multiple other malignancies
[1–6]. Notably, several recent whole exome sequencing
(WES) studies have demonstrated a significant correlation
between the total mutation load (i.e., the complete set of
genes harboring non-synonymous, exonic mutations in a
tumor) and clinical benefit with immune checkpoint
inhibitors [7–9]. Widespread access to WES remains
limited due to infrastructure requirements, cost and
bioinformatic demands. The development of a method
to accurately estimate total mutation load from widely
available NGS gene panels could further personalize the
care of cancer patients by improving patient selection
for immune-based therapies. In order to address this
unmet clinical need, we developed an algorithm to gen-
erate a predicted total mutation load (PTML) from the
mutation status of a tumor from a small set of cancer-
related genes. Several cohorts of patients were used to
determine the accuracy of PTML, and to assess its as-
sociation with clinical outcomes in melanoma and lung
cancer patients treated with immunotherapies.
Methods
Patient cohorts and clinical evaluation
Tumor samples were derived from patients enrolled on
protocols reviewed and approved by the Institutional
Review Board of The University of Texas MD Anderson
Cancer Center. Informed consent was obtained from all
patients. The ipilimumab treatment cohort from MD
Anderson consisted of melanoma patients (n = 76) for
whom our institutional gene mutation panel test was
performed [10]. The adoptive T-cell therapy using ex
vivo expanded tumor infiltrating lymphocytes (TIL)
(ACT-TIL) cohort consisted of melanoma patients
from MD Anderson (n = 36) for whom WES and/or in-
stitutional gene mutation panel testing was performed.
All other sample data has been previously reported [9,
11–16]. Tumors were evaluated using standard cross-
sectional imaging analysis according to study protocol
or standard of care. The clinical outcomes of
progression-free survival (PFS) and overall survival
(OS) were determined from the date of initial treat-
ment to the date of tumor progression and/or death
(or loss to follow-up), respectively.
Derivation of the ATML and PTML
The Cancer Genome Atlas (TCGA) mutation data
from melanoma (SKCM) and lung adenocarcinoma
(LUAD) samples were downloaded from the public
TCGA data repository website of the Broad Institute
(http://gdac.broadinstitute.org). The actual total muta-
tion load (ATML) for each sample was considered as
the sum of somatic, non-synonymous, exonic mutations
of each gene, as derived from WES. A set of 170 cancer-
related genes assayed at our institution (Additional file 1:
Table S1) [10] were used to generate the cancer-specific
PTMLs from the ATMLs of SKCM and LUAD TCGA
samples [11, 17]. First, an unadjusted mutation value for
each of the 170 genes in the panel was determined by
identifying a TCGA sample with the lowest ATML in
which the panel gene was mutated (Additional file 1:
Figure S1A and B). Second, the sum of the unadjusted
mutation values within a sample was compared to the
ATML for that sample by regression analysis (Additional
file 1: Figure S1C and D). Third, an adjusted mutation
value was derived for each of the 170 genes using the
slope of the line of the regression analysis (Additional
file 1: Table S2 and S3). Finally, the PTML for each
sample was generated by taking the sum of the adjusted
mutation values.
Derivation of the melanoma and lung cancer PTML
Derivation of the melanoma PTML was performed by
initially determining an unadjusted gene mutation value
for each of the 170 genes using the publicly available
SKCM TCGA dataset (Additional file 1: Figure S1A).
Any somatic mutation, regardless of “recurrent” or
“non-recurrent” status, was included and silent muta-
tions were excluded. Only one of the 170 genes in the
panel was without a mutation in the 345 melanoma
samples, and thus the remaining 169 genes were used
for the algorithm. For each melanoma sample, the un-
adjusted individual gene mutation value for each of the
169 genes was determined by identifying the lowest
ATML within each TCGA sample to harbor a mutation
in one of the 169 genes in the panel. The sum of the un-
adjusted individual gene mutation values for each of the
169 genes defined the unadjusted total mutation load
for a tumor sample. Regression analysis comparing the
unadjusted total mutation load versus the ATML for
each sample was highly correlated (n = 345, R2 = 0.87,
Additional file 1: Figure S1C), from which the adjusted
individual gene mutation value was then determined
for each gene employing the slope of the regression
line. Summation of each adjusted individual gene muta-
tion value for each of the 169 genes within a sample
provided the PTML for that sample. In cases in which a
gene harbored more than one mutation, the adjusted
individual gene mutation value was multiplied by the
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number of mutations within the gene. The same ap-
proach was taken to derive the lung cancer PTML
using the LUAD TCGA dataset. Ten of the 170 genes
in the panel were without a mutation in the 230 lung
adenocarcinoma samples, and thus the remaining 160
genes were used for the algorithm. Regression analysis
comparing the unadjusted total mutation load versus
the ATML for each sample showed a strong correlation
(n = 230, R2 = 0.76, Additional file 1: Figure S1D) from
which the adjusted individual gene mutation values
were determined for each gene. The following equation





MIN total nonsynonymous exonic mutationsð Þ f or gene k
slope of linear regression
 
where, n = number of genes in the panel, RND denotes
rounding, MIN denotes the minimum of total non-
synonymous, exonic mutations among the samples with
gene k mutated.
The adjusted individual gene mutation value for each
gene differed substantially between the melanoma and
lung adenocarcinoma. For example, a hotspot somatic
mutation in BRAF (common in melanoma) equates to
an adjusted gene mutation value of 7 if present within a
melanoma sample, but garners a value of 22 if mutated
in a lung adenocarcinoma sample (Additional file 1:
Figure S1A and B). Inversely, a somatic mutation in
EGFR (relatively common in lung cancer) equates to an
adjusted gene mutation value of 7 for a lung adenocar-
cinoma sample, but has a value of 29 if present within a
melanoma sample. This observation is consistent with
the relative recurrent nature of these mutations within
these cancer types.
Statistical analyses
Kaplan–Meier analyses and the log-rank tests were per-
formed using the ‘survival’ R package. Adjusted hazard
ratios were determined using a Cox proportional hazards
regression model. Median survival represents the time at
which fractional survival equals 50 % (median50). If sur-
vival exceeds 50 % at the longest time point, then
median survival is deemed “undefined.” The association
of PTML status with serum lactate dehydrogenase
(LDH) level was evaluated using the χ2 test, and with in-
fused TIL number by unequal variance two-sample t-test.
Results
Derivation of PTML in melanoma and lung cancer
samples
We sought to determine if mutations identified within a
small, defined set of genes could be utilized to accurately
predict the total mutation burden determined by WES.
PTML algorithm development included 170 cancer-
related genes that are part of our institutional assay panel
(Additional file 1: Table S1) [10]. The mutation status of
these genes and the ATML were identified for publicly-
available WES mutation (somatic, non-synonymous,
exonic) data from SKCM (n = 345) and LUAD (n = 230)
samples derived from TCGA [10, 11, 17], and was used to
develop and test our PTML algorithm (see Methods). The
PTML value given to each gene, if mutated, differed sub-
stantially between melanoma and lung cancer, indicating
differential association of the 170 cancer-related genes
with the ATML in each cancer type (Additional file 1:
Figure S1A and B; Table S2 and S3).
Validation of PTML using multiple independent
melanoma and lung cancer datasets
In order to validate the melanoma PTML algorithm, re-
gression analysis assessing the PTML versus ATML for
melanoma samples from three (n = 121, n = 127, n = 64)
independent, publicly available WES melanoma datasets
was performed (Fig. 1a) [12–14]. The PTML was
strongly correlated with the ATML from these melan-
oma validation cohorts (R2 = 0.71). Similarly, analysis of
two independent cohorts of lung cancer (all NSCLC,
91 % adenocarcinoma) samples (n = 217) [15, 16] that
had undergone WES also demonstrated a strong correl-
ation between the lung cancer PTML and the ATML of
these validation cohorts (R2 = 0.81, Fig. 1b). These data
show that application of the cancer-specific PTMLs,
derived from a small set of genes, to five unrelated valid-
ation cohorts accurately reflects the total mutation load
within a tumor.
The correlation of adjusted gene mutation values for
melanoma versus lung cancer was extremely poor (R2 =
0.0063, Additional file 1: Figure S2A). Further, applica-
tion of a cancer-specific PTML to a distinctly different
cancer dramatically weakened the correlation between
the PTML and the ATML (R2 = 0.47, melanoma vs. lung
cancer, Additional file 1: Figure S2B). In addition, a
PTML value of zero significantly correlated with an
ATML of less than 100 for both cancers (see dashed
rectangle on x-axes in Fig. 1a, b), suggesting a predictive
cut-off value when no PTML genes are mutated in a re-
spective sample. Finally, the melanoma- and lung
cancer-specific PTMLs derived from our 170 gene panel
showed similar predictive value as the PTML derived
from the most recurrently mutated genes that define
each tumor type by WES, respectively (Additional file 1:
Figure S3A and B).
PTML in both melanoma and lung cancer correlates with
nucleotide alterations associated with exposure to
respective mutagens
The development of cutaneous melanoma and lung cancer
is highly associated with exposure to distinct mutagens:
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ultraviolet (UV) radiation and tobacco smoking, re-
spectively. Ranking melanoma samples from lowest to
highest mutation load revealed a clear association be-
tween samples with lower mutation burdens and low
UV rate (Fig. 2a). We observed a similar association for
lung cancer and never-smoker status (Fig. 2b). Consist-
ent with this observation, the melanoma- and lung can-
cer-specific PTMLs strongly correlated (R2 > 0.90) with
the frequency of UV-mediated and tobacco-induced mu-
tations (Additional file 1: Figure S4) [13, 15]. Notably, a
distinct subset of samples, enriched for, but not exclusively
composed of, low UV rate and never-smoker patient tu-
mors, aggregated below the 100 total mutation threshold.
Clinical utility of PTML in melanoma and lung cancer
immunotherapy
It has been shown that the ATML of a tumor highly cor-
relates with the frequency of potential neoantigens
within that tumor [9, 18]. It is thought that the high
ATML exhibited by melanoma and lung tumors in-
creases the likelihood of generating neoantigens recog-
nized by the immune system, and may play an
important role in the efficacy of immunotherapy in these
cancers [7, 8, 19]. However, as shown in the analysis in
Fig. 2, a distinct subset of melanoma and lung cancer tu-
mors harbor a low ATML (≤ 100), which has been
shown to result in a much lower frequency of potential
Fig. 1 Melanoma and lung cancer have distinct predicted total mutation loads (PTMLs) that predict actual total mutation load (ATML). For validation,
PTML was generated for independent melanoma cohorts (3 pooled cohorts, n = 312, R2 = 0.71; cutaneous only: n = 258, R2 = 0.73) [12–14] (a) and lung
cancer (2 pooled cohorts, n = 217, R2 = 0.81; lung adenocarcinoma (LUAD) only: n = 199, R2 = 0.82) samples (b) [15, 16]. The melanoma- and
lung-specific PTML strongly correlated with the ATML of samples from each cancer type, respectively. The lung cancer PTML performs well for
both LUAD, lung squamous cell carcinoma, and not otherwise specified non-small cell lung carcinoma samples. A PTML score of zero correlates
strongly with an ATML ≤ 100 in both cancers
Fig. 2 Melanoma and lung cancer-specific predicted total mutation loads correlate with specific mutagen exposures and nucleotide alterations.
a Melanoma samples are ranked (x-axis) according to actual total mutation load (ATML) (y-axis), and the UV rate associated with each sample is
displayed by colors (green = less exposure, red =more exposure). b Lung cancer samples are ranked (x-axis) according to ATML (y-axis), and the
smoking status associated with each sample is displayed in color (green = never, red = smoker, gray = no data). Note the relative enrichment, but
not complete constituency, of low UV-rate and never-smokers in less mutated samples, respectively. Samples were derived from the skin cutaneous
melanoma (SKCM; n = 345) and lung adenocarcinoma (LUAD; n = 230) TCGA cohorts [11, 17]. LUSC, lung squamous cell carcinoma samples; NSCLC,
not otherwise specified non-small cell lung carcinoma samples
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neoantigens [9, 18]. This is consistent with recent publi-
cations showing patients with melanoma tumors having
ATMLs less than 100 to have significantly less clinical
benefit from anti-CTLA-4 therapy [9, 14].
Since melanoma- and lung cancer-specific PTMLs sig-
nificantly correlated with ATMLs and the characteristic
nucleotide alterations within each cancer, we determined
if the PTML also correlated with immunotherapy clin-
ical outcomes in each cancer type. The PTML was first
determined for a cohort of metastatic melanoma pa-
tients (n = 76) treated with the FDA-approved immuno-
therapy ipilimumab (anti-CTLA-4) (Additional file 1:
Table S4). OS from the start of ipilimumab therapy was
significantly shorter for patients with a low PTML
(PTML ≤ 100, n = 19, median50 = 582 days) compared to
patients with a higher PTML (PTML > 100, n = 57, me-
dian50 undefined, P = 0.006) (Fig. 3a). The unadjusted
hazard ratio (HR) for low versus high PTML was 0.35
(95 % CI, 0.16–0.77; P = 0.009). After adjustment for
LDH level, a known prognostic factor in metastatic mel-
anoma that also correlates with inferior outcomes with
immunotherapy in this disease [20], as well as for age,
gender and clinical M stage, the HR for high PTML
was 0.272 (95 % CI, 0.11–0.65; P = 0.003). The
adjusted HR for elevated LDH was 4.45 (95 % CI,
1.93–10.8; P = 0.001). Furthermore, application of the
PTML to two independent, previously reported co-
horts of advanced melanoma patients treated with
anti-CTLA-4 and for which WES data was available
(n = 110 and n = 64) [9, 14] also demonstrated a strong
association between the PTML and clinical benefit
(Additional file 1: Figure S5A and B).
ACT-TIL is also an immunotherapy used in the treat-
ment of melanoma [21]. We applied the PTML algorithm
to an independent cohort of metastatic melanoma patients
treated with ACT-TIL (n = 36) at our institution to assess
the correlation between PTML and ACT-TIL clinical out-
come (Additional file 1: Table S5). Patients with low
PTML (n = 8) had significantly shorter PFS and OS than
patients with high PTML (n = 28) (PFS: median50 85 days
vs. 190 days (P < 0.05); and OS: median50, 391 days vs.
1486 days (P < 0.05)) (Fig. 3b, c). Patients in these two
groups did not significantly differ in the mean number of
TILs administered (4.16 × 1010; SD = 1.98 × 1010 and
6.37 × 1010; SD = 3.58 × 1010, respectively, P = 0.11). The
ACT-TIL cohort serum LDH level statistical analysis was
inconclusive given the large confidence interval range,
likely due to the limitations of the cohort size. No signifi-
cant difference in median age (47.5 vs. 50.5 years old) or
male to female ratio was observed between the low and
high PTML patients.
Finally, PTML was determined for a previously reported
cohort of metastatic lung adenocarcinoma patients treated
with pembrolizumab (anti-PD-1) (Fig. 4a–c) [16]. As the
observed distributions of PTMLs in the lung adenocarcin-
oma TCGA supported a threshold value of ≤ 100 non-
synonymous mutations, clinical outcomes were analyzed
by this threshold, which was also the same cut-off for the
melanoma cohorts. None of the lung adenocarcinoma pa-
tients with low PTML (≤ 100; n = 8) achieved a clinical
response (Fig. 4a) or durable clinical benefit (Fig. 4b),
and they had a shorter PFS than patients with high
PTML (n = 21) (4.1 vs. 8.3 months, P = 0.0003, Fig. 4c).
Thus, the lung cancer-specific PTML recapitulated the
clinical correlation results derived from the WES sam-
ple data, and the PTML ≤ 100 threshold separated a sig-
nificant subset of patients with no clinical response/
benefit in this cohort.
Fig. 3 Predicted total mutation load (PTML) correlates with immunotherapy outcomes in melanoma. a Ipilimumab-treated melanoma patients
with a low PTML (≤ 100, n= 19) have a poorer overall survival (OS) compared to high PTML patients (> 100, n = 57). Melanoma patients treated
with adoptive T-cell therapy using ex vivo expanded tumor infiltrating lymphocytes with a low PTML (n = 8) have shorter progression-free survival
(b) and shorter OS (c) compared to high PTML (n = 28) patients (low PTML = red line, high PTML = black line)
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Discussion
In this analysis, we employed WES data from 1104 dis-
tinct tumor samples to derive and validate an algorithm
that accurately predicts the total mutation load for mela-
nomas or lung cancers using results from a set of 170
genes broadly used in NGS cancer gene panels. We
demonstrate that the individual genes were “weighted”
differently depending on tumor type, creating melan-
oma- and lung cancer-specific PTML algorithms.
These cancer-specific PTMLs strongly correlated with
ATMLs from WES in both cancer types, and with clin-
ical outcomes using three distinct immunotherapies
(i.e., anti-CTLA-4, anti-PD-1, and ACT-TIL). These
results suggest that small NGS mutation panels used
to select targeted therapy approaches may also have
utility for the personalized use of immunotherapies.
The relative cost comparison of targeted next gener-
ation sequencing of 169 genes versus WES of 20,000
genes depends on the assessment of multiple variables:
the depth of sequencing, extra reagent expense, differ-
ence in flow cell occupancy, contrast in informatics and
data storage needs, and time costs. We estimate this dif-
ference to be at least 5- to 10-fold greater to perform
targeted next generation sequencing on approximately
200 gene exomes versus WES with current technology
and resources.
The clinical benefit observed in melanoma and lung
cancer to single-agent immunotherapy is thought to be
related to these two tumor types having the highest fre-
quency of gene mutations among common solid can-
cers, and thus increasing the likelihood of generating
neoantigens recognized by the immune system [7, 8,
19]. Multiple WES studies have now shown a signifi-
cant correlation between the total tumor mutation load
and the predicted neoantigen load [9, 14, 18, 22]. In
addition, recent data from the melanoma and lung
adenocarcinoma TCGAs showed a strong association
between total tumor mutation load and immune cyto-
lytic activity within samples, with an abrupt increase in
the immune cytolytic activity within both tumor types
beginning at approximately 100 total mutations within
a tumor [9, 18]. Consistent with this data, a recent
study by Van Allen et al. [9] showed, in an independent
melanoma cohort, that both the mutation/neoantigen
load and the expression of immune cytolytic enzymes
are associated with clinical benefit. Our own analysis of
this data indicates that the combination of mutation load
and cytolytic score results in an even more significant cor-
relation with clinical benefit (unpublished data).
In this study, we observed that patients with a low
PTML (≤ 100) had worse clinical outcomes compared to
patients with a high PTML (> 100) in three independent
advanced melanoma cohorts treated with ipilimumab.
We also report here, for the first time, that low PTML is
associated with significantly shorter PFS and OS in a
cohort of metastatic melanoma patients treated with
ACT-TIL. The correlation between ACT-TIL clinical
outcome and the total mutation load is reinforced by
prior case reports suggesting that benefit from ACT-TIL
may be due to the existence and persistence of clones
within the TIL that recognize neoantigens on the
matched cancer cells [23, 24]. Finally, utilizing the
PTML ≤ 100 threshold, patients with lung adenocarcin-
oma and a low PTML failed to achieve partial tumor
Fig. 4 Predicted total mutation load (PTML) correlates with immunotherapy outcomes in lung adenocarcinoma. Lung adenocarcinoma
patients with a low PTML (≤ 100) treated with pembrolizumab fail to obtain a partial tumor response (a), fail to obtain a durable clinical
response (b), and have a markedly lower progression-free survival (PFS) compared to patients with a high PTML (c) (PFS curve: low PTML = red line,
high PTML = black line)
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response, failed to achieve durable clinical benefit, and
had a lower PFS. Thus, low PTML represented a clinic-
ally worse outcome category in pembrolizumab-treated
lung adenocarcinoma.
Despite the association between tumor mutation load
and clinical outcome in these and other studies, as with
other effective markers in cancer, the relationship be-
tween these variables is not deterministic. Patients with
melanoma or lung cancer that harbor a “low” tumor mu-
tation load can “respond” to immunotherapy and those
with a “high” mutation load may not respond. However,
our analysis across five clinical data sets in two cancer
types indicates that, below a threshold level, the prob-
ability of clinical benefit is significantly lower. Thus, the
total mutation load or the PTML may serve as an
important variable when assessing the potential benefits
of immune-based therapeutics in individual patients. In
addition, the PTML demonstrated efficacy across co-
horts in which distinct tissue procurement, exome cap-
ture/sequencing techniques, mutation calling algorithms,
and different definitions of clinical benefit were used. In
this study, we were agnostic about the specific location
and functionality of a gene mutation and its association
with the ATML. Further studies to enhance the use of
the PTML could focus on standardizing analytic prac-
tices, potentially assigning further weight to functionally
relevant genes/mutation sites and combining the PTML
with other variables that may have predictive value (i.e.,
immune infiltrate or cytolytic score) as has been sug-
gested [9].
There are multiple examples of oncogenic mutations
that predict benefit from FDA-approved targeted ther-
apies (CML/imatinib, melanoma/BRAFi, lung/EGFR
and ALK inhibitors, breast/HER2 inhibitors), and other
mutations that predict resistance (RAS mutations and
EGFR inhibitors). Taken together, these data support
the clinical use of molecular testing to guide personal-
ized cancer treatment [25]. In addition, multiple trials
are currently ongoing in which patients are assigned to
investigational targeted therapy strategies based on the
results of clinical NGS panels. Here, we demonstrate
that the mutation status of a small set of genes, that
could also be used to select rationale targeted therapies,
provides an accurate estimate of the total mutation load
(PTML) which significantly correlates with clinical
benefit from immunotherapy in melanoma and lung
cancer patients. These results provide a new and easily
actionable approach to personalize the care of cancer
patients and to further optimize the use of immune
therapies.
Conclusions
We have developed an innovative algorithmic approach
using large cohorts of melanoma and lung cancer samples
with DNA sequencing data that can predict the total mu-
tation load from a set of less than 170 genes. The pre-
dicted total mutation load from this limited gene set
correlates significantly with immunotherapy outcomes in
melanoma and lung cancer and may have significant util-
ity in the personalized use of immunotherapy in advanced
cancer patients.
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